Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Galapagos NV
Galapagos NV
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Galapagos and NovAliX enter integrated drug discovery collaboration
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development
Galapagos expands fibrosis portfolio
Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development
Pharnext announces R&D agreement with Galapagos
The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development
Galapagos ends inflammation partnership with Janssen
Long-running alliance started in 2007
Research & Development
AbbVie and Galapagos to co-develop cystic fibrosis therapies
Firms aim to start Phase 1 trials at end of 2014
Research & Development
Galapagos appoints CEO of Service Division
David Smith returns to the Belgian firm in new role
Research & Development
Galapagos receives €2.5m grant for IBD research
IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now